(MedPage Today) — The FDA flagged a potential safety signal after four deaths were reported among patients with treatment-resistant schizophrenia who received investigational evenamide in clinical trials, Newron Pharmaceuticals said Thursday…
Source link
Four Deaths Prompt FDA Safety Concerns About Novel Schizophrenia Drug
